10-Q: Precigen Reports First Quarter 2024 Financial Results Amidst Going Concern Uncertainty

Precigen's first quarter 2024 results show a net loss of $23.7 million and highlight substantial doubt about the company's ability to continue as a going concern.

Summary

• Precigen reported a net loss of $23.7 million for the first quarter of 2024, compared to a net loss of $22.7 million for the same period in 2023.
• The company's total revenues decreased to $1.1 million from $1.9 million year-over-year, primarily due to a reduction in service revenues.
• Research and development expenses increased to $14.2 million from $12.2 million year-over-year, driven by increased personnel costs and fees paid to consultants and contract research organizations.
• Selling, general, and administrative expenses decreased to $10.2 million from $11.6 million year-over-year, mainly due to a reduction in stock compensation and insurance expenses.
• As of March 31, 2024, Precigen had $44.8 million in cash, cash equivalents, and short-term investments.
• The company's current cash and investments are not sufficient to fund planned operations through one year after the date the interim financial statements are issued, raising substantial doubt about its ability to continue as a going concern.
• The company is exploring various financing options, including non-dilutive and dilutive financings, as well as strategic alliances and asset sales.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a net loss, declining revenue, and a going concern warning, which overshadows any positive aspects. The need for additional capital and the uncertainty surrounding future operations contribute to a negative sentiment.

Positives

• Selling, general, and administrative expenses decreased by 12.8% year-over-year, indicating cost management efforts.
• The company is actively pursuing various financing options to address its liquidity concerns.

Negatives

• The company experienced a net loss of $23.7 million in Q1 2024.
• Total revenue decreased by 42.5% year-over-year.
• Research and development expenses increased by 17.2% year-over-year.
• There is substantial doubt about the company's ability to continue as a going concern due to insufficient cash reserves.

Risks

• The company's current cash and investments are not sufficient to fund planned operations for the next year.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may be required to delay, reduce the scope of, or eliminate some or all of its operations if it cannot obtain additional capital.
• The company's ability to fund operations is dependent on raising additional capital through various means, which may not be available on commercially acceptable terms or at all.
• The company faces risks related to the research and development of therapeutic product candidates, including dependence on key individuals and intellectual property, competition, and technical risks.

Future Outlook

The company anticipates continuing to incur significant losses for the foreseeable future and will require additional capital to fund its operations and execute its business plan. The company is preparing for a potential launch of PRGN-2012 in 2025, pending regulatory approval.

Management Comments

• Management expects operating losses and negative cash flows from operations to continue for the foreseeable future.
• Management believes that its array of technology platforms uniquely positions it among other biotechnology companies to advance precision medicine.
• Management is exploring various financing options, including non-dilutive and dilutive financings, as well as strategic alliances and asset sales.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on gene and cell therapies. The company's focus on precision medicine and proprietary technology platforms aims to differentiate it from competitors. The company's financial results reflect the challenges and risks inherent in early-stage drug development.

Comparison to Industry Standards

• Precigen's financial results are typical of a clinical-stage biopharmaceutical company with significant R&D expenses and limited revenue.
• Companies like CRISPR Therapeutics and Editas Medicine, which are also in the gene editing space, similarly experience high R&D costs and net losses while advancing their clinical programs.
• Precigen's cash burn rate and need for additional capital are consistent with other companies in the sector that are not yet generating significant product revenue.
• The company's focus on proprietary technology platforms such as UltraCAR-T, AdenoVerse, and ActoBiotics is a common strategy among biotech companies seeking to establish a competitive advantage.
• The going concern warning is not uncommon for companies in this sector that are dependent on future financing and regulatory approvals.

Legal Proceedings

• The company is involved in various legal matters, including governmental investigations.
• The company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the company's business, financial condition, results of operations, or cash flows.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be affected by potential cost-cutting measures or operational changes.
• Customers of Exemplar may experience changes in service availability or pricing.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company plans to submit a BLA under an accelerated approval pathway for PRGN-2012 in the second half of 2024.
• The company is preparing for commercial readiness for a potential launch of PRGN-2012 in 2025, if approved.
• The company will continue to advance its clinical programs, including PRGN-3005, PRGN-3006, PRGN-3007, PRGN-2009, and PRGN-2012.
• The company will continue to explore various financing options to address its liquidity concerns.

Key Dates

Keywords

Precigen, financial results, going concern, net loss, revenue, research and development, biopharmaceuticals, Exemplar, liquidity, capital raise, UltraCAR-T, AdenoVerse, ActoBiotics